JointHealth
français
 
JointHealth™ express   January 12, 2022


Arthritis Consumer Experts (ACE) maps out recent important changes to provincial drug formulary listing decisions and what they mean for Canadians living with inflammatory arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), and osteoporosis.

The following medication has been added to the online version of ACE’s Arthritis Medications Report Card:
  • infliximab (Remsima®, SC) for the treatment of RA
  • romosozumab (Evenity®) for the treatment of osteoporosis
British Columbia

A listing criteria update has occurred for the following medications:
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
The following medication has been declined for listing in the provincial drug formulary:
  • belimumab (Benlysta®) for the treatment of lupus
The following medication has been listed for reimbursement on the provincial drug formulary:
  • rituximab (Riximyo®) for the treatment of vasculitis
Alberta

A listing criteria update has occurred for the following medications:
  • adalimumab (Humira®) for the treatment of RA
  • secukinumab (Cosentyx®) for the treatment of AS and PsA
  • tofacitinib (Xeljanz®) for the treatment of RA
The following medications have been listed for reimbursement on the provincial drug formulary:
  • baricitinib (Olumiant®) for the treatment of RA
  • rituximab (Riabni®) for the treatment of RA
  • rituximab (Riabni®) for the treatment of vasculitis
  • rituximab (Riximyo®) for the treatment of vasculitis
Saskatchewan

A listing criteria update has occurred for the following medications:
  • abatacept (Orencia®) for the treatment of RA and JIA
  • adalimumab (Humira®), etanercept (Enbrel®), etanercept (Brenzys®), and etanercept (Erelzi®) for the treatment of RA, AS, JIA, and PsA
  • anakinra (Kineret®) for the treatment of RA
  • certolizumab pegol (Cimzia®), infliximab (Avsola®), infliximab (Inflectra®), infliximab (Renflexis®), and infliximab (Remicade®) for the treatment of RA, AS, and PsA
  • ixekizumab (Taltz®) and ustekinumab (Stelara®) for the treatment of PsA
  • secukinumab (Cosentyx®) for the treatment of AS and PsA
The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Amgevita®) for the treatment of RA, AS, JIA and PsA
  • adalimumab (Hadlima®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hulio®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hyrimoz®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
  • baricitinib (Olumiant®) for the treatment of RA
Manitoba

The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Amgevita®) for the treatment of RA, AS, JIA and PsA
  • adalimumab (Hadlima®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hulio®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hyrimoz®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
  • baricitinib (Olumiant®) for the treatment of RA
  • infliximab (Avsola®) for the treatment of RA, AS, and PsA
Ontario

A listing criteria update has occurred for the following medications:
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
The following medications have been listed for reimbursement on the provincial drug formulary:
  • baricitinib (Olumiant®) for the treatment of RA
  • rituximab (Riximyo®) for the treatment of vasculitis
Quebec

The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Hyrimoz®) for the treatment of JIA
  • baricitinib (Olumiant®) for the treatment of RA
  • infliximab (Remsima®, SC) for the treatment of RA
  • rituximab (Truxima®) for the treatment of vasculitis
  • romosozumab (Evenity®) for the treatment of osteoporosis
  • upadacitinib (Rinvoq®) for the treatment of PsA
Nova Scotia

The following medication have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Amgevita®) for the treatment of RA, AS, JIA and PsA
  • adalimumab (Hadlima®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hulio®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hyrimoz®) for the treatment of RA, AS, and PsA
  • adalimumab (Idacio®) for the treatment of RA, AS, and PsA
  • etanercept (Brenzys®) for the treatment of JIA and PsA
New Brunswick

The following medication has been declined for listing in the provincial drug formulary:
  • ixekizumab (Taltz®) for the treatment of AS
The following medication has been listed for reimbursement on the provincial drug formulary:
  • baricitinib (Olumiant®) for the treatment of RA
Newfoundland & Labrador

A listing criteria update has occurred for the following medications:
  • tofacitinib (Xeljanz®) for the treatment of RA
  • secukinumab (Cosentyx®) for the treatment of AS
The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Hadlima®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hyrimoz®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
  • rituximab (Riximyo®) for the treatment of vasculitis
  • rituximab (Ruxience®) for the treatment of RA and vasculitis
  • rituximab (Truxima®) for the treatment of RA and vasculitis
Prince Edward Island

The following medications have been listed for reimbursement on the provincial drug formulary:
  • adalimumab (Amgevita®) for the treatment of RA, AS, and PsA
  • adalimumab (Hadlima®) for the treatment of RA, AS, and PsA
  • adalimumab (Hulio®) for the treatment of RA, AS, and PsA
  • adalimumab (Hyrimoz®) for the treatment of RA, AS, and PsA
  • adalimumab (Idacio®) for the treatment of RA, AS, and PsA
  • rituximab (Riximyo®) for the treatment of RA and vasculitis
  • rituximab (Ruxience®) for the treatment of RA and vasculitis
  • rituximab (Truxima®) for the treatment of RA and vasculitis
NIHB

The following medications have been listed for reimbursement:
  • adalimumab (Amgevita®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hadlima®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hulio®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Hyrimoz®) for the treatment of RA, AS, JIA, and PsA
  • adalimumab (Idacio®) for the treatment of RA, AS, JIA, and PsA
  • infliximab (Avsola®) for the treatment of RA, AS, and PsA
Yukon

The following medications have been listed for reimbursement on the Yukon drug formulary:
  • adalimumab (Amgevita®) for the treatment of RA, AS, and PsA
  • adalimumab (Hulio®) for the treatment of RA, AS, and PsA
  • ixekizumab (Taltz®) for the treatment of PsA